Revenue
2021
2022
2023
2024
Valion Bio, Inc. (VBIO)
Price—Loading quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | — | $780,000 | $1.2M | $1.8M | $1.3M |
| Gross profit | — | $2,000 | $287,000 | $299,000 | −$38,000 |
| Research & development | $3.1M | $1.3M | $1.7M | $1.7M | $878,000 |
| Operating expenses | $7.9M | $4.5M | $8.5M | $10.4M | $5.6M |
| Operating income | −$7.9M | −$4.5M | −$8.2M | −$10.1M | −$5.6M |
| EBITDAderived | — | −$4.5M | −$8.2M | −$10.1M | — |
| Net income | −$8.9M | −$5.7M | −$8.2M | −$10.1M | −$8.5M |
| Basic EPSper diluted share | -$7.84 | -$19.68 | -$176.80 | -$104.32 | -$2.43 |
| Diluted EPSper diluted share | — | -$19.68 | -$176.80 | -$104.32 | -$2.43 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 15, 2026Form 4 | Bolton SheryleDirector | BuyCommon Stock | 10.0K | $1.04 | $10.4K | 10.0K |
| Apr 1, 2026Form 4 | Valauri Christina RizopoulosDirector | BuyCommon Stock | 19.0K | $0.95 | $18.1K | 19.0K |